Bengaluru-based Infosys--the country's second-largest IT firm--has staged a strong quarterly performance and raised the lower ...

EBITDA dropped 8 percent partly due to lower coffee prices impacting its non-branded business, though net profit rose 15 ...

Backed by large deals, Infosys raised the lower end of its guidance to 1 per cent from nil growth it had guided a quarter ...

The focus has now shifted to Semaglutide, the GLP-1 agonist being pursued as a generic version of Ozempic/Wegovy.

GIFT Nifty hints at a positive start; heavy Q1 earnings, expiry, macro data, and global momentum to guide market mood.

BENGALURU: Infosys delivered a resilient performance in a challenging environment, outperforming other tier-1 players and ...

BioMarin downgraded to Hold amid rising competition, pipeline concerns, and ambitious growth targets, despite solid Q1 2025 ...

The drugmaker plans to launch Semaglutide in 87 countries next year, including those where patents are expiring and emerging ...

Q1 Results Today: Amid the ongoing earnings season, Nestle India, Bajaj Finance, Canara Bank, Indian Bank, APL Apollo Tubes, Adani Energy Solutions, ACC, Cyient, Ujjwal Small Finance Bank, and V-Mart ...

The company announced an all-cash acquisition transaction with Harmony at $12.25 per share, with court hearing scheduled for July 30 and shareholder vote planned for August 29. Liquidity: $196 million ...

Coforge's board of directors at their meeting held on July 23 declared interim dividend of Rs 4 per share, for the FY2025-26.

Mobile's record-breaking Q2 2025 achievements, including customer growth, ARPA gains, and innovative launches like T-Satellite.